SeaBeLife develops patented molecules that inhibit regulated necrosis, specifically targeting necroptosis and ferroptosis, to protect vital organs from damage caused by acute diseases such as liver failure and renal injury. Their therapeutic approach has shown efficacy in preclinical models, offering potential treatments for conditions currently lacking effective alternatives.
Funding
$5.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many acute and chronic diseases, such as liver failure, renal injury, age-related macular degeneration, and neurodegenerative disorders, cause irreparable damage to vital organs due to regulated cell death. Current treatments are often ineffective in limiting the progressive and irreversible damage caused by these diseases. There is a need for therapeutic alternatives that can directly protect cells from regulated necrosis, specifically necroptosis and ferroptosis.
Solution
SeaBeLife is developing a new class of drug candidates designed to simultaneously block necroptosis and ferroptosis, two forms of regulated necrosis, to protect organs under attack from disease. Their molecules have demonstrated the ability to inhibit both cell death mechanisms, reducing inflammation and oxidative stress that is deleterious to surrounding tissues. This therapeutic approach has shown efficacy in preclinical models of hepatotoxicity, renal failure, and ocular pathologies. SeaBeLife's dual-action inhibitors offer a potential solution for diseases currently lacking effective therapeutic alternatives, including acute hepatic insufficiency, age-related macular degeneration, and Parkinson's disease. The company's lead candidate, SBL01, has received Orphan Drug Designation from the EMA for the treatment of acute liver failure.
Target Audience
The primary target audience includes patients suffering from acute and orphan (rare) diseases with limited therapeutic options, specifically those affected by acute hepatic insufficiency, acute renal failure, myocardial infarctions, strokes, age-related macular degeneration, and neurodegenerative diseases like Parkinson's and Alzheimer's.
Features
- Dual inhibition of necroptosis and ferroptosis with a single molecule
- Demonstrated efficacy in preclinical models of acute liver injury, acute renal failure, and ocular pathologies
- Protection of cells from inflammation and oxidative stress caused by regulated necrosis
- SBL#1 (IntraVenous) for Acute liver injury (ALI) / Acute liver failure (AHI)
- SBL#2 (Intravitreal injection) for Macular degeneration (POC in dry AMD and Stargardt's disease)
- SBL#OXs
- Drug Discovery in progress for Neurodegenerative diseases